Supplementary Data — Losartan for COVID-19: real-time meta-analysis of 7 studies

October 2026

Losartan COVID-19 outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Puskarich (DB RCT)−2%1.02 · 0.07–15.88ICU1/581/59 Puskarich (DB RCT)−205%3.05 · 0.33–28.49hosp.3/581/59 Puskarich (DB RCT)−27%1.27 · 0.36–4.50progression5/584/59 Geriak (RCT)6%0.94 · 0.06–13.69death1/161/15COVID-ARB Geriak (RCT)53%0.47 · 0.05–4.65ICU1/162/15COVID-ARB Geriak (RCT)53%0.47 · 0.05–4.65no disch.1/162/15COVID-ARB Puskarich (DB RCT)−3%1.03 · 0.47–2.27death11/10111/104ALPS-IP Puskarich (DB RCT)−26%1.26 · 0.54–2.91death11/1019/104ALPS-IP Puskarich (DB RCT)−27%1.27 · 0.71–2.27ventilation21/10017/103ALPS-IP Puskarich (DB RCT)3%0.97 · 0.89–1.07oxygen89/10194/104ALPS-IP Freilich (RCT)−533%6.33 · 0.43–92.54death4/90/3COVIDMED Freilich (RCT)−160%2.60 · 0.43–15.66hosp. time9 (n)3 (n)COVIDMED Götberg (RCT)1%0.99 · 0.06–15.63death1/1511/149 Götberg (RCT)77%0.23 · 0.07–0.78ventilation3/15113/149 Götberg (RCT)36%0.64 · 0.31–1.32ICU11/15117/149 Tran (RCT)−14%1.14 · 0.57–2.15death16/17116/170ARBs CORONA II Tran (RCT)−10%1.10 · 0.49–2.41death11/17110/170ARBs CORONA II Tran (RCT)−1%1.01 · 0.70–1.38ventilation49/17048/168ARBs CORONA II Tran (RCT)−3%1.03 · 0.94–1.10oxygen149/170144/170ARBs CORONA II Tran (RCT)−75%1.75 · 0.69–3.93ICU11/786/77ARBs CORONA II Simeone (RCT)37%0.63 · 0.18–2.14death4/357/39 Simeone (RCT)36%0.64 · 0.20–1.99death4/357/39 Simeone (RCT)27%0.73 · 0.40–1.31ventilation11/3217/36 Simeone (RCT)37%0.63 · 0.27–1.50oxygen time32 (n)36 (n) Simeone (RCT)0%1.00 · 0.72–1.38oxygen time32 (n)36 (n) Simeone (RCT)33%0.67 · 0.21–2.11misc.34 (n)39 (n) Simeone (RCT)4%0.96 · 0.89–1.04viral load35 (n)39 (n)
00.511.52+
Rotate screen for more detailsIncrease width for more details
← Losartan
reduces risk
Losartan
increases risk →
Fig. S1. All outcomes.